Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Net Margin (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Net Margin for 10 consecutive years, with 125.87% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Margin rose 555.0% year-over-year to 125.87%, compared with a TTM value of 130.59% through Sep 2025, down 14718.0%, and an annual FY2024 reading of 253.94%, down 269981.0% over the prior year.
  • Net Margin was 125.87% for Q3 2025 at Spero Therapeutics, down from 12.01% in the prior quarter.
  • Across five years, Net Margin topped out at 150.89% in Q4 2022 and bottomed at 12200.4% in Q1 2022.
  • Average Net Margin over 5 years is 1961.7%, with a median of 358.59% recorded in 2021.
  • The sharpest move saw Net Margin soared 4680767bps in 2021, then plummeted -1193595bps in 2022.
  • Year by year, Net Margin stood at 177.61% in 2021, then surged by 185bps to 150.89% in 2022, then plummeted by -2190bps to 3153.85% in 2023, then soared by 91bps to 275.48% in 2024, then soared by 54bps to 125.87% in 2025.
  • Business Quant data shows Net Margin for SPRO at 125.87% in Q3 2025, 12.01% in Q2 2025, and 236.07% in Q1 2025.